Loxo's Larotrectinib Requires Paradigm-Change In Clinical Practice

The TRK inhibitor won over ASCO with deep and durable responses across 17 cancer types, but diagnostics will be the true test of the tumor-agnostic approach – and the focus of Loxo's commercial strategy.